2023年6月12日

挪威深科技创业带来的系列临床CyPep-1发展到2800万美元,first-in-class靶向肿瘤细胞膜免疫疗法Bergen-based临床阶段immune-oncology启动Cytovation ASA已成功获得了额外的800万美元(nokia 85米)在一系列一轮融资,与从现有投资者Sandwater和Canica参与。本系列最新资金的涌入带来的总该公司超过2800万美元的资金。Cytovation,成为受人尊敬的公司的卑尔根大学关注CyPep-1的发展,一个创新的免疫疗法,以目标肿瘤细胞选择性。通过创建毛孔在肿瘤细胞膜,CyPep-1触发免疫反应,提高肿瘤特异性免疫。新鲜的投资将支持Cytovation促进会的首席资产,CyPep-1,进入了一个全面的第二阶段计划,旨在解决实体肿瘤。以其独特的综合作用机理,CyPep-1将改变治疗实体肿瘤的景观。专门针对癌症细胞中磷脂,促进毛孔在质膜的形成。这个过程不仅释放抗原,免疫系统也促进炎症微环境。因此,它刺激肿瘤特异性免疫反应类似于原位接种疫苗,从而消除癌细胞。Cytovation首席执行官Lars Prestegarden,医学博士,说:“我们很高兴宣布这一最新一轮融资的成功结束后我们最初的一个2000万美元的2022年1月,允许我们提前CyPep-1对临床概念验证阶段2。 We continue to make excellent progress in our ongoing Phase 1/2 CICILIA solid tumor basket trial, and with our IND in hand we will now expand clinical development to the US. We look forward to announcing initial results from CICILIA, including in combination with pembrolizumab, in the second half of 2023.” The financing round extension was co-led by existing investors Sandwater, a Norwegian venture capital firm that invests in ground-breaking companies with a positive impact across a range of industries including life science, and Canica, a large, privately owned investment company operating out of Norway and Switzerland that is focused on building highly innovative companies that aim to create value for investors and society. Cytovation also welcomed participation from several new investors reflecting the growing interest in the potential of CyPep-1 as a first-in-class targeted tumor membrane immunotherapy. Cytovation’s 57-patient Phase 1/2 CICILIA solid tumor basket trial is now well advanced, with top line results due in H2 2023. The Phase 2a monotherapy expansion arm builds on strong Phase 1 monotherapy data, which demonstrated a favorable safety profile along with early signals of efficacy in several tumor types. CICILIA also includes an arm in which CyPep-1 is combined with pembrolizumab, as part of an ongoing clinical trial collaboration and supply agreement with Merck/MSD. Cytovation is seeking to develop CyPep-1 in selected neoplastic orphan indications that may allow an expedited pathway to a first approval, while supporting the broader potential of CyPep-1 across a range of solid tumors. Given the significant potential of CyPep-1, Cytovation recently announced the expansion of its senior management team with the hiring of Iman Barilero, PharmD, PhD, as Chief Development Officer, and Helen Blanco, MBA, as VP Operations. These new team members will be central to the Company’s mission to develop CyPep-1 to enhance the lives of cancer patients suffering from a variety of solid tumors.